Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Catanzaro

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Clinical Genitourinary Cancer|September 7, 2014
Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapyAndrea Necchi, Patrizia Giannatempo, Biagio Paolini, et al.
Clinical Genitourinary Cancer|July 22, 2014
A prognostic model including pre- and postsurgical variables to enhance risk stratification of primary mediastinal nonseminomatous germ cell tumors: the 27-year experience of a referral centerAndrea Necchi, Patrizia Giannatempo, Salvatore Lo Vullo, et al.
JCO Precision Oncology|August 18, 2025
Targeting Cyclin-Dependent Kinase 4 Amplifications: A Pioneering Case of Metastatic Leydig Cell Tumor Responding to AbemaciclibAmedeo Nuzzo, Marco Barella, Melanie Claps, et al.
Minerva Urology and Nephrology|January 27, 2026
Management of monorchid patients with previous testis cancer: the role of frozen sections and the real possibility of testis sparing surgery in a large retrospective seriesSebastiano Nazzani, Ruggero Darisi, Mario Catanzaro, et al.
Urologic Oncology|May 20, 2015
Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogationDaniele Raggi, Luigi Mariani, Patrizia Giannatempo, et al.
BJU International|March 17, 2020
Optimising the selection of candidates for neoadjuvant chemotherapy amongst patients with node-positive penile squamous cell carcinomaMarco Bandini, Maarten Albersen, Juan Chipollini, et al.
Urologic Oncology|October 4, 2021
Risk factors and survival outcomes for upstaging after inguinal lymph node dissection for cN1 penile squamous cell carcinomaNicholas H Chakiryan, Aaron Dahmen, Marco Bandini, et al.
The Journal of Urology|May 25, 2021
Patterns of Recurrence following Inguinal Lymph Node Dissection for Penile Cancer: Optimizing Surveillance StrategiesNicholas H Chakiryan, Aaron Dahmen, Marco Bandini, et al.
The Journal of Urology|August 11, 2021
Reply by AuthorsNicholas H Chakiryan, Aaron Dahmen, Marco Bandini, et al.
Urology|July 19, 2023
Predicting Limited Survival Following Inguinal Lymph Node Dissection in Penile Cancer: Should We Revisit the Goals of Care?Lee A Hugar, Taylor C Peak, Mahrukh Naqvi, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Clinical Genitourinary Cancer|September 7, 2014
Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapyAndrea Necchi, Patrizia Giannatempo, Biagio Paolini, et al.
Clinical Genitourinary Cancer|July 22, 2014
A prognostic model including pre- and postsurgical variables to enhance risk stratification of primary mediastinal nonseminomatous germ cell tumors: the 27-year experience of a referral centerAndrea Necchi, Patrizia Giannatempo, Salvatore Lo Vullo, et al.
JCO Precision Oncology|August 18, 2025
Targeting Cyclin-Dependent Kinase 4 Amplifications: A Pioneering Case of Metastatic Leydig Cell Tumor Responding to AbemaciclibAmedeo Nuzzo, Marco Barella, Melanie Claps, et al.
Minerva Urology and Nephrology|January 27, 2026
Management of monorchid patients with previous testis cancer: the role of frozen sections and the real possibility of testis sparing surgery in a large retrospective seriesSebastiano Nazzani, Ruggero Darisi, Mario Catanzaro, et al.
Urologic Oncology|May 20, 2015
Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogationDaniele Raggi, Luigi Mariani, Patrizia Giannatempo, et al.
BJU International|March 17, 2020
Optimising the selection of candidates for neoadjuvant chemotherapy amongst patients with node-positive penile squamous cell carcinomaMarco Bandini, Maarten Albersen, Juan Chipollini, et al.
Urologic Oncology|October 4, 2021
Risk factors and survival outcomes for upstaging after inguinal lymph node dissection for cN1 penile squamous cell carcinomaNicholas H Chakiryan, Aaron Dahmen, Marco Bandini, et al.
The Journal of Urology|May 25, 2021
Patterns of Recurrence following Inguinal Lymph Node Dissection for Penile Cancer: Optimizing Surveillance StrategiesNicholas H Chakiryan, Aaron Dahmen, Marco Bandini, et al.
The Journal of Urology|August 11, 2021
Reply by AuthorsNicholas H Chakiryan, Aaron Dahmen, Marco Bandini, et al.
Urology|July 19, 2023
Predicting Limited Survival Following Inguinal Lymph Node Dissection in Penile Cancer: Should We Revisit the Goals of Care?Lee A Hugar, Taylor C Peak, Mahrukh Naqvi, et al.
Pageof 7